Meier A, Sander P, Schaper K J, Scholz M, Böttger E C
Institut für Medizinische Mikrobiologie, Medizinische Hochschule Hannover, Germany.
Antimicrob Agents Chemother. 1996 Nov;40(11):2452-4. doi: 10.1128/AAC.40.11.2452.
Quantitative susceptibility testing of clinical isolates of streptomycin-resistant Mycobacterium tuberculosis demonstrated that there is a close correlation between the molecular resistance mechanism and the in vitro activity of streptomycin: mutations in rpsL were mainly associated with high-level resistance, mutations in rrs were associated with an intermediate level of resistance, and streptomycin-resistant isolates with wild-type rpsL and rrs exhibited a low-level resistance phenotype. Investigations of streptomycin-resistant isolates with wild-type rpsL and rrs revealed that (i) there is no cross-resistance to other drugs and (ii) a permeability barrier may contribute to resistance, because resistance was significantly lowered in the presence of a membrane-active agent.
对耐链霉素结核分枝杆菌临床分离株进行的定量药敏试验表明,分子耐药机制与链霉素的体外活性之间存在密切相关性:rpsL基因突变主要与高水平耐药相关,rrs基因突变与中等水平耐药相关,而具有野生型rpsL和rrs的耐链霉素分离株表现出低水平耐药表型。对具有野生型rpsL和rrs的耐链霉素分离株的研究表明:(i)对其他药物无交叉耐药性;(ii)通透性屏障可能导致耐药,因为在存在膜活性剂的情况下耐药性显著降低。